… Therefore, this study will overstate the true difference in cost-effectiveness of these cancer
drugs listed in the US and England. However, even if payers were able to achieve the …

… , means the current cost trajectory is untenable for most healthcare systems to sustain. …
IO drugs and those in clinical development are reviewed. The issue of cost effectiveness vs. …

… cost effectiveness of a targeted OAM was primarily based on what was concluded in the
study; only when no conclusion was made in the study did we determine the cost effectiveness …

… We assess the average cost-effectiveness in the US in 2014 of new cancer drugs approved
… the number of drugs ever approved, controlling for the change in cancer incidence and mean …

… cost of contemporary cancer drugs signals even greater costs for future drugs (Table) . …
Because of this fact, there is no competition among truly effective cancer drugs to lower their cost. …

… Of the 116 drug approvals, we found between 1 and 9 cost effectiveness studies (median,
3). Of the 228 studies, 49 (21%) were funded directly by a pharmaceutical company, 53 (23%) …

… We aimed to assess the association between the clinical benefit of approved cancer drugs
based on these frameworks and their drug prices in the USA and four European countries (…

… in the cost-effectiveness of various specialist oncological drugs, in the adjuvant and
metastatic phases. The first part of the paper will be targeted to reviewing pairs of cost-effectiveness …

… Drugs must meet several criteria to enter the fund: they must have the potential to be cost
effective at the current price, and there must be uncertainty about their clinical effectiveness …

… cost-effectiveness of medical care in Japan. The present study was to determine the direct
costs of molecular-targeting drugs … incremental cost-effectiveness ratio (ICER) and the cost per …